search
Back to results

CompaRison of Paresthesia Mapping to anatomIc Midline-based burSt Programming Strategies (CRISP)

Primary Purpose

Chronic Pain

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Paresthesia mapping lead evaluation first
Anatomical midline lead evaluation first
Sponsored by
Abbott Medical Devices
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Pain

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject is able to provide informed consent to participate in the study;
  • Subject is 18 years of age or older;
  • Subject has failed to respond to at least 6 months of conventional treatment including pharmacological treatment, physical therapy, epidural injections and/or radiofrequency therapy as per NICE Tag 0159;
  • FBSS subjects with predominant low back pain;
  • Subject has a lower back pain intensity of at least 6.0 out of 10.0 on the VAS at baseline;
  • Subject is on stable pain medications with a total opioid equivalent of 120 mgs a day or less for at least 28 days prior to enrolling in this study, and is willing to stay on those medications with no dose adjustments until activation of the permanently implanted SCS device;
  • Subject's medical record has been evaluated by the Investigator to ensure that the subject is a good candidate for a neurostimulation system;
  • Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all office visits;
  • Female candidates of child-bearing potential agree to commit to the use of an effective method of contraception (including but not limited to sterilization, barrier devices, oral contraceptives, intrauterine devices (IUDs), condoms, rhythm method, or abstinence) for the duration of the study

Exclusion Criteria:

  • Subjects with significant scoliosis even if surgically corrected
  • Subject is currently participating in a clinical investigation that includes an active treatment arm;
  • Subject has been implanted with or participated in a trial period for a neurostimulation system;
  • Subject has an infusion pump;
  • Subject has evidence of an active disruptive psychological or psychiatric disorder as determined as per standard of care;
  • Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease or uncontrolled diabetes mellitus;
  • Subject has a current diagnosis of a progressive neurological disease as determined by the Investigator;
  • Subject is immunocompromised;
  • Subject has an existing medical condition that is likely to require repetitive MRI evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma, tumor);
  • Subject has history of cancer requiring active treatment in the last 12 months;
  • Subject has an existing medical condition that is likely to require the use of diathermy in the future;
  • Subject has documented history of allergic response to titanium or silicone;
  • Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection;
  • Female candidates of child bearing potential that are pregnant (confirmed by positive urine/blood pregnancy test).

Sites / Locations

  • Seacroft Hospital
  • St. Thomas Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Anatomical midline lead first

Paresthesia mapping lead first

Arm Description

subjects in this group will receive stimulation first using an anatomical midline placed lead and subsequently using a paresthesia mapping placed lead

subjects in this group will receive stimulation first using a paresthesia mapping placed lead and subsequently using an anatomical midline placed lead

Outcomes

Primary Outcome Measures

Visual Analog Scale (VAS) for Back Pain at SCS Trial
Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)

Secondary Outcome Measures

Visual Analog Scale (VAS) for Back Pain at 3 Months
Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)
Visual Analog Scale (VAS) for Back Pain at 6 Months
Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)
Visual Analog Scale (VAS) for Back Pain at 12 Months
Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)
EQ-5D at SCS Trial
Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)
EQ-5D at 3 Month
Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)
EQ-5D at 6 Month
Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)
EQ-5D at 12 Month
Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)
ODI at SCS Trial
questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)
ODI at 3 Months
questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)
ODI at 6 Months
questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)
ODI at 12 Months
questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)
Satisfaction Questionnaire
questionnaire regarding patient satisfaction with the therapy
Satisfaction Questionnaire
questionnaire regarding patient satisfaction with the therapy
Satisfaction Questionnaire
questionnaire regarding patient satisfaction with the therapy

Full Information

First Posted
December 2, 2016
Last Updated
April 6, 2021
Sponsor
Abbott Medical Devices
Collaborators
St Thomas, Seacroft Hospital, Leeds
search

1. Study Identification

Unique Protocol Identification Number
NCT02986074
Brief Title
CompaRison of Paresthesia Mapping to anatomIc Midline-based burSt Programming Strategies
Acronym
CRISP
Official Title
CompaRison of Paresthesia Mapping to anatomIc Midline-based burSt Programming Strategies
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
November 2016 (Actual)
Primary Completion Date
August 19, 2019 (Actual)
Study Completion Date
August 19, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Abbott Medical Devices
Collaborators
St Thomas, Seacroft Hospital, Leeds

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The study will compare therapeutic efficacy of a novel spinal cord stimulation leads implant based on anatomical landmarks with standard surgical implantation technique.
Detailed Description
The primary purpose of this study is to compare the therapeutic efficacy of the conventional, paresthesia mapping-based burst spinal cord stimulation (SCS) implantation strategy to a more novel, anatomic midline-based approach that has the potential to streamline the workflow associated with the SCS treatment continuum.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Anatomical midline lead first
Arm Type
Experimental
Arm Description
subjects in this group will receive stimulation first using an anatomical midline placed lead and subsequently using a paresthesia mapping placed lead
Arm Title
Paresthesia mapping lead first
Arm Type
Experimental
Arm Description
subjects in this group will receive stimulation first using a paresthesia mapping placed lead and subsequently using an anatomical midline placed lead
Intervention Type
Device
Intervention Name(s)
Paresthesia mapping lead evaluation first
Intervention Description
Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using paresthesia mapping in the first part of the SCS trial and using the lead implanted using anatomical midline placement in the second part of the SCS trial
Intervention Type
Device
Intervention Name(s)
Anatomical midline lead evaluation first
Intervention Description
Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using anatomical midline in the first part of the SCS trial and using the lead implanted using paresthesia mapping placement in the second part of the SCS trial
Primary Outcome Measure Information:
Title
Visual Analog Scale (VAS) for Back Pain at SCS Trial
Description
Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)
Time Frame
after 2 weeks of SCS trial
Secondary Outcome Measure Information:
Title
Visual Analog Scale (VAS) for Back Pain at 3 Months
Description
Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)
Time Frame
3 months after activation of permanent SCS implant
Title
Visual Analog Scale (VAS) for Back Pain at 6 Months
Description
Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)
Time Frame
6 months after activation of permanent SCS implant
Title
Visual Analog Scale (VAS) for Back Pain at 12 Months
Description
Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)
Time Frame
12 months after activation of permanent SCS implant
Title
EQ-5D at SCS Trial
Description
Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)
Time Frame
after 2 weeks of SCS trial
Title
EQ-5D at 3 Month
Description
Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)
Time Frame
3 months after activation of permanent SCS implant
Title
EQ-5D at 6 Month
Description
Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)
Time Frame
6 months after activation of permanent SCS implant
Title
EQ-5D at 12 Month
Description
Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)
Time Frame
12 months after activation of permanent SCS implant
Title
ODI at SCS Trial
Description
questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)
Time Frame
first SCS trial assessment (up to two weeks after electrodes implantation)
Title
ODI at 3 Months
Description
questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)
Time Frame
3 months after activation of permanent SCS implant
Title
ODI at 6 Months
Description
questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)
Time Frame
6 months after activation of permanent SCS implant
Title
ODI at 12 Months
Description
questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)
Time Frame
12 months after activation of permanent SCS implant
Title
Satisfaction Questionnaire
Description
questionnaire regarding patient satisfaction with the therapy
Time Frame
3 month follow up
Title
Satisfaction Questionnaire
Description
questionnaire regarding patient satisfaction with the therapy
Time Frame
6 month follow up
Title
Satisfaction Questionnaire
Description
questionnaire regarding patient satisfaction with the therapy
Time Frame
12 month follow up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject is able to provide informed consent to participate in the study; Subject is 18 years of age or older; Subject has failed to respond to at least 6 months of conventional treatment including pharmacological treatment, physical therapy, epidural injections and/or radiofrequency therapy as per NICE Tag 0159; FBSS subjects with predominant low back pain; Subject has a lower back pain intensity of at least 6.0 out of 10.0 on the VAS at baseline; Subject is on stable pain medications with a total opioid equivalent of 120 mgs a day or less for at least 28 days prior to enrolling in this study, and is willing to stay on those medications with no dose adjustments until activation of the permanently implanted SCS device; Subject's medical record has been evaluated by the Investigator to ensure that the subject is a good candidate for a neurostimulation system; Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all office visits; Female candidates of child-bearing potential agree to commit to the use of an effective method of contraception (including but not limited to sterilization, barrier devices, oral contraceptives, intrauterine devices (IUDs), condoms, rhythm method, or abstinence) for the duration of the study Exclusion Criteria: Subjects with significant scoliosis even if surgically corrected Subject is currently participating in a clinical investigation that includes an active treatment arm; Subject has been implanted with or participated in a trial period for a neurostimulation system; Subject has an infusion pump; Subject has evidence of an active disruptive psychological or psychiatric disorder as determined as per standard of care; Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease or uncontrolled diabetes mellitus; Subject has a current diagnosis of a progressive neurological disease as determined by the Investigator; Subject is immunocompromised; Subject has an existing medical condition that is likely to require repetitive MRI evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma, tumor); Subject has history of cancer requiring active treatment in the last 12 months; Subject has an existing medical condition that is likely to require the use of diathermy in the future; Subject has documented history of allergic response to titanium or silicone; Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection; Female candidates of child bearing potential that are pregnant (confirmed by positive urine/blood pregnancy test).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lalit Venkatesan, Ph.D.
Organizational Affiliation
Abbott Medical Devices
Official's Role
Study Director
Facility Information:
Facility Name
Seacroft Hospital
City
Leeds
State/Province
Yorkshire And The Humber
ZIP/Postal Code
LS14 6UH
Country
United Kingdom
Facility Name
St. Thomas Hospital
City
London
ZIP/Postal Code
SE1 7EH
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

CompaRison of Paresthesia Mapping to anatomIc Midline-based burSt Programming Strategies

We'll reach out to this number within 24 hrs